-
Aclaris Announces Phase 3 Results, Will Submit NDA In Q1 2017
Wednesday, November 16, 2016 - 12:13pm | 361Aclaris Therapeutics Inc (NASDAQ: ACRS), a small-cap clinical-stage specialty pharmaceutical company that commercializes drugs for the treatment of ermatological indications, announced after Tuesday's close results from two Phase 3 trials. Aclaris' two pivotal Phase 3 trials have been...